Clinical Trial Update: 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial update evaluating 123I‑MIBG scintigraphy for evaluating patients with suspected neuroendocrine tumors, including pheochromocyto…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor
• Medullary Thyroid Carcinoma
• Neuroblastoma
• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• Iodine-123 metaiodobenzylguanidine (123I-MIBG) (metaiodobenzylguanidine)

Snippet

Sponsor: Vancouver Coastal Health | Conditions: Pheochromocytoma, Neuroblastoma | Phase 3 | Status: UNKNOWN